Overview

Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma

Status:
Withdrawn
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics in adolescent and adult subjects with intermittent or mild to moderate persistent asthma.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Brodalumab